Related Experiment Videos
Neuronal nicotinic acetylcholine receptors as novel drug targets
1SIBIA Neurosciences Inc., La Jolla, California, USA.
The Journal of Pharmacology and Experimental Therapeutics
|January 20, 2000
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Investigational new drugs·2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Current cancer drug targets·2011
Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.
Bioorganic & medicinal chemistry letters·2003
The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
The Journal of pharmacology and experimental therapeutics·2003
SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.
The Journal of pharmacology and experimental therapeutics·2001
Ranolazine inhibits invasiveness of human breast cancer cells in combination with a tyrosine kinase inhibitor: Dose-dependent synergy.
The Journal of pharmacology and experimental therapeutics·2026
A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats.
The Journal of pharmacology and experimental therapeutics·2026
Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed/refractory diffuse large B-cell lymphoma: An exploratory clinical study.
The Journal of pharmacology and experimental therapeutics·2026
Calpeptin and protein kinase C inhibition suppress exosome-associated inflammatory signaling and epidermal dysregulation in a 3-dimensional psoriatic skin model.
The Journal of pharmacology and experimental therapeutics·2026
Adiponectin in cigarette smoke-induced epithelial-mesenchymal transition.
The Journal of pharmacology and experimental therapeutics·2026
CE9A215 (inotodiol) ameliorates oxazolone-induced atopic dermatitis by targeting mast cells and proinflammatory cytokines.
The Journal of pharmacology and experimental therapeutics·2026
Short-term heart rate variability is preserved in Parkinson's disease under atomoxetine.
Brain communications·2026
Goreisan-mediated suppression of chemokine and cytokine production in astrocytes under AQP4-expressing conditions.
Frontiers in neuroscience·2026
Switching to Angiotensin Receptor-Neprilysin Inhibitor and Reduced Risk of New-Onset Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction: A Nationwide Propensity Score-Matched Study.
European heart journal. Cardiovascular pharmacotherapy·2026